Wyeth said Friday it has ended its partnership with Solvay Pharmaceuticals to develop and market bifeprunox and other early-stage compounds as treatments for schizophrenia and other psychiatric conditions.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments